Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18796201 | 0.94 | MCL1 (0.49) | MCL1MAPK1CYP1A2RECQLCA1 | |
| SCHEMBL4751506 | 0.79 | MCL1 (0.46) | MCL1MAPK1CYP1A2RECQLCA1 | |
| SCHEMBL28595966 | 0.76 | MCL1 (0.40) | MCL1MAPK1CYP1A2RECQL | |
| SCHEMBL10192793 | 0.76 | ALDH1A1 (0.45) | CA1CA2CA4KMT2AALDH1A1 | |
| 2-Acetylcyclopentanone SCHEMBL22289653 | 0.76 | — | — | |
| 2-Acetylcyclopentanone SCHEMBL12565037 | 0.76 | — | — | |
| 2-Acetylcyclopentanone SCHEMBL535830 | 0.76 | — | — | |
| SCHEMBL3107746 | 0.75 | MCL1 (0.50) | MCL1MAPK1CYP1A2RECQLCA1 | |
| SCHEMBL172131 | 0.75 | CYP1A2 (0.44) | MCL1MAPK1CYP1A2RECQLALDH1A1 | |
| SCHEMBL3780480 | 0.75 | MAPK1 (0.41) | MCL1MAPK1CYP1A2RECQLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688063-B2 | Treating and/or preventing insulin-resistance related weight gain | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-23 | — | — | US | disclosed |
| US-20180028488-A1 | TREATING AND/OR PREVENTING INSULIN-RESISTANCE RELATED WEIGHT GAIN | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-02-01 | — | — | US | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028488-A1 | TREATING AND/OR PREVENTING INSULIN-RESISTANCE RELATED WEIGHT GAIN | IGFBP1, IGFBP2, ACACA | MCL1 4562/4885MAPK1 1718/4885CYP1A2 2812/4885 |
| US-10688063-B2 | Treating and/or preventing insulin-resistance related weight gain | IGFBP1, IGFBP2, ACACA | MCL1 4562/4885MAPK1 1718/4885CYP1A2 2812/4885 |
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | MCL1 1400/4885MAPK1 1145/4885CYP1A2 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.